qulipta 12-week safety

Well tolerated
across patients

Safety established in all doses1

Adverse reactions for QULIPTA™ and Placebo Adverse reactions for QULIPTA™ and Placebo Adverse reactions for QULIPTA™ and Placebo

QULIPTA IS A MIGRAINE PREVENTIVE WITH NO CONTRAINDICATIONS1

Study included patient populations with a history of gastrointestinal disorders (31%) or psychiatric disorders (43%). Mean age: 41 years, 88% female, 80% white, 17% black, 12% Hispanic or Latino. Study included patient populations with a history of gastrointestinal disorders (31%) or psychiatric disorders (43%). Mean age: 41 years, 88% female, 80% white, 17% black, 12% Hispanic or Latino. Study included patient populations with a history of gastrointestinal disorders (31%) or psychiatric disorders (43%). Mean age: 41 years, 88% female, 80% white, 17% black, 12% Hispanic or Latino.

A DECREASE IN WEIGHT WAS OBSERVED1

The proportion of patients with a weight decrease of at least 7% at any point was 4.9% for QULIPTA 60 mg, 3.2% for QULIPTA 30 mg, 3.8% for QULIPTA 10 mg, and 2.8% for placebo.1

see efficacy data